SCHEDULE 13G/A: BlackRock Discloses 8.3% Stake in Dexcom Inc. Common Stock

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 8.3% of Dexcom Inc.'s common stock as of March 31, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 8 to Schedule 13G regarding its beneficial ownership in Dexcom Inc. (CUSIP: 252131107).
• As of March 31, 2025, BlackRock, Inc. beneficially owns an aggregate of 32,504,140 shares of Dexcom Inc. common stock.
• This ownership represents 8.3% of the total outstanding common stock of Dexcom Inc.
• BlackRock holds sole voting power over 29,986,509 shares and sole dispositive power over 32,504,140 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Dexcom Inc.
• Various BlackRock subsidiaries and affiliates contribute to this aggregate ownership, with no single person's interest exceeding five percent of the total outstanding common shares.

Sentiment

Score: 7

Explanation: The document is a routine ownership disclosure, indicating a significant, passive institutional investment. While not directly positive news about company performance, a large stake by a major investor like BlackRock is generally viewed favorably as a sign of confidence.

Positives

• BlackRock's significant stake (8.3%) indicates a substantial institutional investment in Dexcom Inc., signaling confidence from a major asset manager.
• The filing confirms the investment is for ordinary course of business, not for control, suggesting a passive, potentially long-term investment perspective.

Future Outlook

The document is a Schedule 13G filing, which is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Dexcom Inc.'s future performance or BlackRock's investment strategy beyond the stated purpose of holding shares in the ordinary course of business.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

This filing reflects a significant institutional investment by BlackRock, one of the world's largest asset managers, in Dexcom Inc., a leading company in the medical device industry, particularly known for continuous glucose monitoring (CGM) systems. Such a substantial stake by a major institutional investor can be seen as a vote of confidence in the company's long-term prospects within the healthcare technology sector.

Comparison to Industry Standards

• This document is a standard Schedule 13G filing, which reports beneficial ownership. It does not provide financial results or operational metrics that would allow for a direct comparison to industry standards or specific comparable companies/projects.
• The 8.3% ownership stake by BlackRock is a significant institutional holding, common for large asset managers investing in established companies like Dexcom Inc. within the medical technology sector.

Stakeholder Impact

• Shareholders: Provides transparency on a major institutional investor's stake, potentially influencing market perception and confidence.
• Company Management: Awareness of a significant, passive institutional holder.

Next Steps

• BlackRock, Inc. will continue to file amendments to Schedule 13G if there are material changes to its beneficial ownership of Dexcom Inc. common stock.

Key Dates

Keywords

BlackRock, Dexcom Inc., Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, DXCM